Overview

Efficacy of Changing to TRAVATAN® From Prior Therapy

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Travoprost